VIVA BIOTECH (01873.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec15

Sobi Acquires Arthrosi, Via Bio Expected to Gain Nearly $40 Million

01:37

Oct28

ZS Securities Optimistic About VivaBio's CRO Business Growth Prospects

07:08

Sep29

Viatris Biotech Wins 2025 Asia-Pacific Technology Innovation Leadership Award

04:02

Sep10

Guosheng Securities Gives BUY Rating to Viva Biotech with Revenue Growth Forecast

02:16

Sep3

China Merchants Securities Releases Report on Venus Biopharm's 2025 Mid-Year Report

07:32

Aug28

VIVA BIOTECH released FY2025 Q1 earnings on August 28 (BJT), actual revenue HKD 445.46 M, actual EPS HKD 0.0267

15:00

Schedules & Filings

Schedules

Filings

Aug28

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 455.25 M, Net Income 66.66 M, EPS 0.0273

Mar27

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 534.49 M, Net Income 26.85 M, EPS 0.0096

Aug29

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 527.5 M, Net Income 62.76 M, EPS 0.0268

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change